Thermo Fisher Scientific Inc. (TMO) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-26

Business type: Franchise

How it makes money

Thermo Fisher earns revenue by supplying life science consumables and analytical instruments alongside contract drug development and manufacturing services.

Thermo Fisher operates across four business segments: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics.

The Laboratory Products and Biopharma Services segment generates revenue by providing lab supplies alongside outsourced drug development, clinical trials management, and commercial manufacturing through brands like Patheon and PPD.

The Life Sciences Solutions segment supplies reagents and consumables for biosciences and bioproduction, while Analytical Instruments provides mass spectrometry and electron microscopy tools. Specialty Diagnostics delivers diagnostic test kits and reagents.

What protects it: the moat

Thermo Fisher deploys 14,000 sales personnel and technical specialists to embed its products and supply-chain management services inside customer operations.

Thermo Fisher maintains customer relationships through a direct sales force that includes technical specialists trained to support complex laboratory workflows.

The company reinforces customer retention by offering product standardization and integrated supply-chain management services, which lower procurement costs and embed Thermo Fisher into customer workflows.

What growth costs

Thermo Fisher expands its capabilities through continuous research expenditures, targeted acquisitions like Olink, and ongoing operational restructuring.

Thermo Fisher requires ongoing capital allocation toward internal research and development to update its scientific technologies and maintain product performance.

The company routinely acquires complementary businesses to expand segment portfolios, such as acquiring proteomics provider Olink Holding AB and purchasing Solventum Corporation's bioproduction filtration business.

To manage inflation and optimize its cost structure, Thermo Fisher executes operational restructuring programs involving facility consolidations and workforce reductions.

What could damage it

Chinese government regulations requiring local suppliers could compel state-backed institutions to substitute Thermo Fisher's laboratory equipment with domestic vendors.

Thermo Fisher faces potential impairment if international trade regulations or local purchasing mandates restrict access to key growth markets.

In China, regulatory policies requiring or favoring local suppliers create incentives for government-backed research and healthcare customers to shift procurement to domestic competitors, directly threatening Thermo Fisher's revenues in the region.

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

More on TMO

Other companies in Diagnostics & Research